Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib 5-days-on/2-days-off versus standard 3-weeks-on/1-week-off in third-line metastatic colorectal cancer
ChiCTR2000032297Phase 4Recruiting
- Sponsor
- Anhui Provincial Tumor Hospital
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of regorafenib in colorectal cancer (CRC) (2 arms), sponsored by Anhui Provincial Tumor Hospital. Primary endpoint: Progression-free survival. Started May 2020; status: recruiting.
02
Drugs
regorafenib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2000032297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000032297.